05:31 , Dec 15, 2017 |  BC Extra  |  Preclinical News

A new role for Bcl-XL in fibrosis

In a paper published in Science Translational Medicine, researchers from Harvard Medical School and colleagues suggest that inhibiting the anti-apoptotic protein Bcl-XL could treat fibrosis and describe a cell-based assay to stratify scleroderma patients into...
07:00 , Jun 18, 2015 |  BC Innovations  |  Translation in Brief

Watershed crystal

Beryllium LLC and The Broad Institute of MIT and Harvard have found a way to crystallize myeloid leukemia cell differentiation protein (MCL1) that can be used for both its free and ligand-bound forms. The partners...
08:00 , Feb 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: BCL2-associated agonist of cell death (BAD); Bcl2 homology domain 3 (BH3)

Endocrine/metabolic disease INDICATION: Diabetes In vitro and rodent studies suggest mimetics of the phosphorylated BH3 domain of BAD could help treat type 1 diabetes. In rat and mouse pancreatic cells, a BAD BH3 mimetic protected against stress-induced...
08:00 , Dec 4, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer Adenomatous polyposis coli (APC); BH3 interacting domain death agonist (BID) Studies in mice and patient...
07:00 , Aug 14, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens One-bead, one-compound peptoid-encoded a-helix mimetic library to identify chaperones or inhibitors of protein-protein interactions Cell culture studies suggest...
07:00 , Jun 24, 2013 |  BC Week In Review  |  Clinical News

PraediCare Dx: Data

An analysis of peripheral blood mononuclear cells (PBMCs) or bone marrow aspirates from 62 newly diagnosed AML patients showed that Eutropic's PraediCare Dx test predicted patient response to cytarabine-based treatment regimens with 90% accuracy. Additionally,...
08:00 , Feb 28, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer BCL2-associated X protein (BAX); BCL2-antagonist/killer 1 (BAK1; BAK); B cell lymphoma 2 (BCL-2; BCL2); BCL2 homology domain...
08:00 , Feb 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer BCL2-associated X protein (BAX); BCL2-antagonist/killer 1 (BAK1; BAK); B cell lymphoma 2 (BCL-2; BCL2); BCL3 homology...
08:00 , Nov 15, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Bcl2 homology domain 3 (BH3)-derived peptides to predict patient outcome in acute myelogenous leukemia (AML) A BH3 peptide-based assay could...
07:00 , Jun 28, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute myelogenous leukemia (AML) BCL2-like 11 apoptosis facilitator (BCL2L11; BIM) A study...